CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cumberland Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cumberland Pharmaceuticals, Inc.
1600 West End Avenue, Suite 1300
Phone: (615) 255-0068p:615 255-0068 NASHVILLE, TN  37203  United States Ticker: CPIXCPIX
Business Summary
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer A. J.Kazimi 67 2/1/2016 1/1/1999
Chief Financial Officer, Vice President John M.Hamm 69 1/1/2023 5/17/2021
Vice President - Organizational Development Todd M.Anthony 64
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CPIX
Cumberland Emerging Technologies, Inc.
Cumberland Pharma Sales Corp.
Cumberland Pharmaceuticals Inc.
SANCUSO®

General Information
Number of Employees: 93 (As of 12/31/2025)
Outstanding Shares: 14,983,107 (As of 8/4/2026)
Shareholders: 87
Stock Exchange: NASD
Federal Tax Id: 621765329
Fax Number: (615) 255-0094


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, September 20, 2026